Lyell Immunopharma Says its Relapsed Large B-Cell Lymphoma Therapy Receives US FDA's REMAT Designation

MT Newswires Live

2025/04/15

Lyell Immunopharma (LYEL) said Tuesday its therapy candidate for treating relapsed or refractory large B-cell lymphoma, LYL314, has received the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation.

The RMAT designation provides all the benefits of Fast Track and Breakthrough Therapy designations, Lyell said. The FDA's designation drew on initial findings from an ongoing phase 1/2 trial, the company said.

Two pivotal trials are expected to start in mid-2025 and early 2026, the company added.

Shares of the company were up 3% in recent Tuesday trading.

Price: 0.46, Change: +0.01, Percent Change: +3.13

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2527446313"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527446313\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527446313?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-15 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527446313","market":"hk","top_or_hot":-1,"title":"Lyell Immunopharma Says its Relapsed Large B-Cell Lymphoma Therapy Receives US FDA's REMAT Designation","media":"MT Newswires Live","content":"<html><body><p> Lyell Immunopharma (LYEL) said Tuesday its therapy candidate for treating relapsed or refractory large B-cell lymphoma, LYL314, has received the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation.</p><p>The RMAT designation provides all the benefits of Fast Track and Breakthrough Therapy designations, Lyell said. The FDA's designation drew on initial findings from an ongoing phase 1/2 trial, the company said.</p><p>Two pivotal trials are expected to start in mid-2025 and early 2026, the company added.</p><p>Shares of the company were up 3% in recent Tuesday trading.</p><p>Price: 0.46, Change: +0.01, Percent Change: +3.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lyell Immunopharma Says its Relapsed Large B-Cell Lymphoma Therapy Receives US FDA's REMAT Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLyell Immunopharma Says its Relapsed Large B-Cell Lymphoma Therapy Receives US FDA's REMAT Designation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-04-15 22:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Lyell Immunopharma (LYEL) said Tuesday its therapy candidate for treating relapsed or refractory large B-cell lymphoma, LYL314, has received the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation.</p><p>The RMAT designation provides all the benefits of Fast Track and Breakthrough Therapy designations, Lyell said. The FDA's designation drew on initial findings from an ongoing phase 1/2 trial, the company said.</p><p>Two pivotal trials are expected to start in mid-2025 and early 2026, the company added.</p><p>Shares of the company were up 3% in recent Tuesday trading.</p><p>Price: 0.46, Change: +0.01, Percent Change: +3.13</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴資本持倉","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2527446313","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527446313","pubTimestamp":1744728362,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lyell Immunopharma  said Tuesday its therapy candidate for treating relapsed or refractory large B-cell lymphoma, LYL314, has received the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation.The RMAT designation provides all the benefits of Fast Track and Breakthrough Therapy designations, Lyell said. The FDA's designation drew on initial findings from an ongoing phase 1/2 trial, the company said.Two pivotal trials are expected to start in mid-2025 and early 2026, the company added.Shares of the company were up 3% in recent Tuesday trading.Price: 0.46, Change: +0.01, Percent Change: +3.13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4539":"次新股","BK4139":"生物科技","LYEL":"Lyell Immunopharma, Inc."},"translate_title":"Lyell Immunopharma称其复发性大B细胞淋巴瘤疗法获得美国FDA REMAT认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LYEL":1},"content_text":"Lyell Immunopharma (LYEL) said Tuesday its therapy candidate for treating relapsed or refractory large B-cell lymphoma, LYL314, has received the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation.The RMAT designation provides all the benefits of Fast Track and Breakthrough Therapy designations, Lyell said. The FDA's designation drew on initial findings from an ongoing phase 1/2 trial, the company said.Two pivotal trials are expected to start in mid-2025 and early 2026, the company added.Shares of the company were up 3% in recent Tuesday trading.Price: 0.46, Change: +0.01, Percent Change: +3.13","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}